DelveInsight’s, “Diabetic Neuropathy Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Diabetic Neuropathy pipeline landscape. It covers the Diabetic Neuropathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Diabetic Neuropathy Pipeline Report

• DelveInsight’s Diabetic Neuropathy pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Diabetic Neuropathy treatment.
• The leading companies working in the Diabetic Neuropathy Market include Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical, and others.
• Promising Diabetic Neuropathy Pipeline Therapies in the various stages of development include E2007 (2 mg), Trazodone 20 mg, trazodone/gabapentin 2.5/25 mg, DA-9801 300mg, and others.
• September 2023: AstraZeneca announced a study of phase 2 clinical trials for MEDI7352. This is a study investigating the effect of MEDI7352 on chronic pain in patients with painful diabetic neuropathy. The study incudes a screening period of up to 45 days and a 12-week treatment period during which MEDI7352 or placebo will be administered intravenously (IV) on 6 occasions, with each dose separated by 14 days. There will be a 6-week follow-up period.
• September 2023: UCB Pharma announced a study of phase 3 clinical trials for Lacosamide. SP746 (NCT00546351) is a multi-center, open-label, follow-on trial. The purpose of this trial is to assess safety and tolerability of long-term exposure of lacosamide (previously referred to as SPM 927) in subjects with painful distal diabetic neuropathy.

 

Request a sample and discover the recent advances in Diabetic Neuropathy Treatment Drugs @ Diabetic Neuropathy Pipeline Report

 

In the Diabetic Neuropathy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Diabetic Neuropathy clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Neuropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Diabetic Neuropathy Overview

Diabetic Neuropathy, is nerve damage that can occur in people with diabetes. Different types of nerve damage cause different symptoms. Symptoms can range from pain and numbness in your feet to problems with the functions of your internal organs, such as your heart and bladder.

 

Find out more about Diabetic Neuropathy Therapeutics Assessment @ Diabetic Neuropathy Preclinical and Discovery Stage Products

 

Diabetic Neuropathy Emerging Drugs Profile

• Nidufexor: Novartis
• SER 150: Serodus
• GFB 887: Goldfinch Bio

 

Diabetic Neuropathy Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the Diabetic Neuropathy therapies. The Diabetic Neuropathy companies which have their Diabetic Neuropathy drug candidates in the most advanced stage, i.e. Phase II include, Serodus.

 

Learn more about the emerging Diabetic Neuropathy Pipeline Therapies @ Diabetic Neuropathy Clinical Trials Assessment

 

Scope of the Diabetic Neuropathy Pipeline Report

• Coverage- Global
• Diabetic Neuropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Diabetic Neuropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Diabetic Neuropathy Companies- Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical, and others.
• Diabetic Neuropathy Pipeline Therapies- E2007 (2 mg), Trazodone 20 mg, trazodone/gabapentin 2.5/25 mg, DA-9801 300mg, and others.

 

Dive deep into rich insights for new drugs for Diabetic Neuropathy treatment, Visit @ Diabetic Neuropathy Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Diabetic Neuropathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetic Neuropathy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre Registration)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. End Stage Products (Phase III)
11. Drug name : Company name
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. GFB 887: Goldfinch Bio
15. Drug profiles in the detailed report…..
16. Early Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Diabetic Neuropathy Key Companies
21. Diabetic Neuropathy Key Products
22. Diabetic Neuropathy- Unmet Needs
23. Diabetic Neuropathy- Market Drivers and Barriers
24. Diabetic Neuropathy- Future Perspectives and Conclusion
25. Diabetic Neuropathy Analyst Views
26. Diabetic Neuropathy Key Companies
27. Appendix

 

For further information on the Diabetic Neuropathy Pipeline therapeutics, reach out to Diabetic Neuropathy Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking